[Prevention of recurrence of superficial tumors of the bladder with intravesical epirubicin]. / Profilaxis de la recidiva en tumores vesicales superficiales con epirrubicina endovesical.
Actas Urol Esp
; 14(2): 112-4, 1990.
Article
em Es
| MEDLINE
| ID: mdl-2378265
ABSTRACT
Twenty-six patients with surface vesical tumor receiving epirubicin are included for prophylaxis of relapse following surgical exeresis. The dosage used was 15 endovesical instillations of 50 mg in 50 cc sterile water, one instillation a week during the first month followed by once monthly to complete a year. After an average follow-up of 14 months a percentage of 19% relapses were observed with a relapse are of 1.3. Toxic events were seen in 46.1% of cases, and were almost exclusively chemical cystitis. Due to intractable vesical intolerance 5 patients were withdrawn from the study. Epirubicin was shown to be effective in reducing the relapse rate but showed a high incidence of chemical cystitis.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Epirubicina
/
Recidiva Local de Neoplasia
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Revista:
Actas Urol Esp
Ano de publicação:
1990
Tipo de documento:
Article